Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

Olodanrigan (EMA401)

For research use only.

Catalog No.S0326 Synonyms: PD-126055, Olodanrigan free acid, (S) PD-126055

CAS No. 1316755-16-4

Olodanrigan (EMA401, (S) PD-126055) is a highly selective, orally active, peripherally restricted antagonist of angiotensin II type 2 receptor (AT2R). Olodanrigan (EMA401) analgesic action appears to involve the inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.

Size Price Stock Quantity  
USD 427 In stock
USD 1289 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective Angiotensin Receptor Inhibitors

Biological Activity

Description Olodanrigan (EMA401, (S) PD-126055) is a highly selective, orally active, peripherally restricted antagonist of angiotensin II type 2 receptor (AT2R). Olodanrigan (EMA401) analgesic action appears to involve the inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.

Protocol

References

Solubility (25°C)

Chemical Information

Molecular Weight
Formula
CAS No. 1316755-16-4
Storage powder
in solvent
Synonyms PD-126055, Olodanrigan free acid, (S) PD-126055
Smiles COC1=C(C2=C(CN(C(C2)C(=O)O)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4)C=C1)OCC5=CC=CC=C5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04675398 Not yet recruiting Device: Summit RC+S Parkinson Disease University of California San Francisco|Michael J. Fox Foundation for Parkinson''s Research|Burroughs Wellcome December 1 2021 Not Applicable
NCT04287543 Withdrawn Drug: Melatonin|Drug: Placebos Parkinson Disease Instituto Mexicano del Seguro Social May 2021 Phase 2|Phase 3
NCT04620980 Not yet recruiting Diagnostic Test: targeted resequencing Parkinson Disease Neuromed IRCCS March 1 2021 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy Olodanrigan (EMA401) | Olodanrigan (EMA401) supplier | purchase Olodanrigan (EMA401) | Olodanrigan (EMA401) cost | Olodanrigan (EMA401) manufacturer | order Olodanrigan (EMA401) | Olodanrigan (EMA401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID